GlassScriptPhysician profile
Andre F Hall
NPI 1780645572
$1,930.16
in general payments reported to CMS, 2019-2025
30 companies · $295 in 2025
The $295 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $492 · 2020: $77.07 · 2021: $365 · 2022: $345 · 2023: $174 · 2024: $182 · 2025: $295.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $651.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $650.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $243.54 | 2019-2022 | |
| Therapeuticsmd, INC. | $216.82 | 2019-2021 | |
| Coopersurgical, INC. | $141.81 | 2021-2025 | Paragard T 380a, Paragard T 380a |
| Exeltis, USA INC. | $138.68 | 2019-2025 | Slynd |
| Bayer Healthcare Pharmaceuticals INC. | $116.28 | 2019-2025 | |
| Hologic Sales and Service, LLC | $95.51 | 2019-2024 | Thinprep 2000 Processor, Aptima, Acessa Provu System |
| Daiichi Sankyo INC. | $91.68 | 2019-2023 | Injectafer |
| Avion Pharmaceuticals | $88.74 | 2019-2022 | |
| Roche Diagnostics Corporation | $74.68 | 2019-2020 | |
| Vertical Pharmaceuticals, LLC | $71.86 | 2019 | |
| Currax Pharmaceuticals LLC | $64.47 | 2021-2025 | Contrave |
| Pfizer INC. | $57.14 | 2022-2025 | |
| Evofem Biosciences, INC. | $53.53 | 2021 | |
| Organon LLC | $46.89 | 2022-2024 | |
| Shield Therapeutics INC | $41.30 | 2022-2024 | Accrufer |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Agile Therapeutics, INC. | $39.79 | 2021-2024 | Twirla |
| Astellas Pharma US INC | $38.05 | 2025 | Veozah |
| Biogen, INC. | $36.55 | 2025 | Zurzuvae |
| Novo Nordisk INC | $35.93 | 2022-2023 | Wegovy, Saxenda |
| Mylan Pharmaceuticals INC. | $30.89 | 2021 | |
| Lilly USA, LLC | $29.55 | 2024-2025 | Zepbound |
| Urovant Sciences INC | $25.94 | 2022 | |
| Duchesnay USA Incorporated | $25.58 | 2019 | |
| Mission Pharmacal Company | $23.82 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.67 | 2019 | |
| Sumitomo Pharma America, INC. | $18.96 | 2023 | Myfembree |
| Heron Therapeutics, INC. | $18.80 | 2022 | |
| Lsi Solutions INC | $17.56 | 2023 | Fornisee |
| Merck Sharp & Dohme LLC | $13.33 | 2020 | |
| Amgen INC. | $12.81 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andre Hall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.